Trius Therapeutics to Host Analyst and Investor Update Call

        Print
| Source: Trius Therapeutics, Inc.

SAN DIEGO, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, today announced that it will hold an analyst and investor update call Thursday, November 15, 2012 at 4:15 p.m. Eastern Time (1:15 p.m. Pacific Time). During the call, management will provide commercial and clinical updates for Trius' lead compound, tedizolid phosphate, and Andrew Shorr, MD, MPH from Washington Hospital Center will present his thoughts on the current dynamics in the antibacterial space. The conference call will be webcast live under the Investors section of Trius' website at http://investor.triusrx.com/events.cfm, where it will be archived for 30 days following the call. Please connect to Trius' website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The Company's lead investigational drug, tedizolid phosphate, is a once daily, IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI. Trius has two Special Protocol Assessments with the FDA for its two Phase 3 ABSSSI trials and has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S., Canada and the European Union. In addition to the Company's tedizolid phosphate clinical program, Trius has initiated IND-enabling studies for its Gyrase-B development candidate with potent activity against Gram-negative bacterial pathogens including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas. The Gyrase-B program is one of the two preclinical programs supported by federal contracts. For more information, visit www.triusrx.com.

Public Relations Contact:
Laura Kempke/Andrew Law at MSLGroup

781-684-0770

Investor Relations Contact:
Stefan Loren at Westwicke Partners, LLC

443-213-0507